Authors : Evangelos Doukiantzakis, Vasilios Pergialiotis, Laskarina-Maria Korou, Panagiotis Konstantopoulos, Christos Verikokos and Despina Perrea
Abstract: Visfatin is a relatively novel adipokine which gained ground in current research during the last years and the research on its contribution in the pathogenesis of atherosclerosis is ongoing. This study aimed to investigate the effects of combined rosuvastatin and exercise treatment on serum visfatin levels and on other biomarkers related to lipid metabolism and inflammation in mice receiving an atherogenic diet. Thirty five C57BL/6 male mice were assigned to four groups, group A: control, group B: atherogenic fed animals, group C: atherogenic animals along with exercise-training on treadmill and group D: rosuvastatin treatment (0.3 mg kg–1 body weight/day per os) along with exercise training. The duration of the study was 12 weeks. Rosuvastatin treatment in combination to physical exercise resulted in improved serum lipid levels and reducedserum visfatin, sirtuin-1, adiponectin and HMW adiponectin levels in comparison to the non-treated animals. Rosuvastatin treatment of mice combined with exercise effectively reduces serum visfatin levels in atherogenic fed mice. This reduction is directly related to a concurrent reduction of serum total adiponectin and HMW adiponectin levels.
Evangelos Doukiantzakis, Vasilios Pergialiotis, Laskarina-Maria Korou, Panagiotis Konstantopoulos, Christos Verikokos and Despina Perrea, 2015. Serum Visfatin Levels in an Atherosclerotic Animal Model Treated with Rosuvastatin Combined with Physical Exercise. Journal of Animal and Veterinary Advances, 14: 244-249.